Switching from Dupilumab to Upadacitinib: Practice-Informing Evidence from LEVEL UP SWITCH This exclusive video interview with Dr. Christopher Bunick unveils the practice-changing insights of the LEVEL UP SWITCH study, designed…
Read More
Zabalafin’s All-In-One Assault On Inflammation, Infection, Dryness, and Itch Atopic dermatitis has long been driven by a vicious circle—staph overgrowth, immune flare-ups, parched skin, and relentless itch that feed one…
Read More
Catch Up on the Latest Think about the last time you saw real-world data reshape your treatment approach—what if you discovered that one of our most trusted biologics behaves differently…
Read More
From the Vault: The Heterogeneity of Atopic Dermatitis Atopic dermatitis (AD) isn’t a single-symptom disease, and treating it like one may shortchange your patients. A focused review in a JDD…
Read More
Access Inequity in Atopic Dermatitis Care: Are Your Patients Getting Left Behind? Gentle skin care is a foundation of atopic dermatitis (AD) treatment, but what happens when patients can’t afford,…
Read More
Could an Eczema Treatment Also Protect the Heart? Looking at Upadacitinib and Cardiovascular Risk Atopic dermatitis (AD) may start on the skin, but its impact goes much deeper. As a…
Read More
Taming the Flare: A Practical Algorithm for Managing Atopic Dermatitis with or without Infection For patients with atopic dermatitis (AD), flares aren’t just a passing inconvenience, they can be emotionally…
Read More
Explore JDDonline If you’re on the hunt for expert-led, handpicked resources on atopic dermatitis, you’re in the right place. Whether you're brushing up on the latest treatment insights or looking…
Read More
Are Atopic Dermatitis Clinical Trials Becoming More Inclusive? Atopic dermatitis (AD) affects over 31 million people in the U.S., disproportionately impacting racial and ethnic minorities who often experience greater disease…
Read More
Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups
JDD Spotlight: Dupilumab Shows Rapid, Sustained Relief for Lichenification in AD A new pooled analysis from five clinical trials has revealed that dupilumab significantly improves lichenification in moderate to severe…
Read More
By Allison Sit The American Academy of Dermatology (AAD) is joining with other specialties in speaking out about cuts to the Medicare Physician Fee Schedule for 2025. The physician services…
Read More
JDD Article Highlights Vitiligo research is often inconsistent when it comes to measuring disease severity, making it challenging to compare treatment outcomes. The IDEOM Vitiligo Workgroup has begun efforts to…
Read More
